785 related articles for article (PubMed ID: 23864173)
1. Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty.
Schousboe JT; Brown GA
J Bone Joint Surg Am; 2013 Jul; 95(14):1256-64. PubMed ID: 23864173
[TBL] [Abstract][Full Text] [Related]
2. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery.
Mahmoudi M; Sobieraj DM
Pharmacotherapy; 2013 Dec; 33(12):1333-40. PubMed ID: 23625693
[TBL] [Abstract][Full Text] [Related]
4. Cost-effective prophylaxis against venous thromboembolism after total joint arthroplasty: warfarin versus aspirin.
Mostafavi Tabatabaee R; Rasouli MR; Maltenfort MG; Parvizi J
J Arthroplasty; 2015 Feb; 30(2):159-64. PubMed ID: 25534862
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
6. Prophylaxis against venous thromboembolism after arthroplasty: establishing value requires more than one perspective. Commentary on an article by John T. Schousboe, MD, PhD, and Gregory A. Brown, MD, PhD: "Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty".
Yates AJ
J Bone Joint Surg Am; 2013 Jul; 95(14):e102 1-2. PubMed ID: 23864185
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness of enoxaparin versus aspirin in the prevention of venous thromboembolism after total hip or knee arthroplasty: an analysis from the CRISTAL cluster-randomized trial.
CRISTAL Economic Analysis Study Group
Bone Joint J; 2024 Jun; 106-B(6):589-595. PubMed ID: 38821513
[TBL] [Abstract][Full Text] [Related]
8. Effect of age on cost-effectiveness of unicompartmental knee arthroplasty compared with total knee arthroplasty in the U.S.
Ghomrawi HM; Eggman AA; Pearle AD
J Bone Joint Surg Am; 2015 Mar; 97(5):396-402. PubMed ID: 25740030
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism.
Aujesky D; Smith KJ; Cornuz J; Roberts MS
Thromb Haemost; 2005 Mar; 93(3):592-9. PubMed ID: 15735815
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
McCullagh L; Tilson L; Walsh C; Barry M
Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
[TBL] [Abstract][Full Text] [Related]
12. Staged venous thromboemolic events prophylaxis with low-molecular-weight heparin followed by aspirin is safe and effective after arthroplasty.
Asopa V; Cobain W; Martin D; Keene G; Bauze A
ANZ J Surg; 2015 Sep; 85(9):652-7. PubMed ID: 25997601
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty.
Skedgel C; Goeree R; Pleasance S; Thompson K; O'brien B; Anderson D
J Bone Joint Surg Am; 2007 Apr; 89(4):819-28. PubMed ID: 17403806
[TBL] [Abstract][Full Text] [Related]
15. Potent Anticoagulation Does Not Reduce Venous Thromboembolism in High-Risk Patients.
Tan TL; Foltz C; Huang R; Chen AF; Higuera C; Siqueira M; Hansen EN; Sing DC; Parvizi J
J Bone Joint Surg Am; 2019 Apr; 101(7):589-599. PubMed ID: 30946192
[TBL] [Abstract][Full Text] [Related]
16. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of aspirin in prevention of venous thromboembolism after total joint arthroplasty].
Tian H; Song F; Zhang K; Liu Y
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(47):3349-52. PubMed ID: 18478950
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of prolonged thromboprophylaxis after cancer surgery.
Bradley CT; Brasel KJ; Miller JJ; Pappas SG
Ann Surg Oncol; 2010 Jan; 17(1):31-9. PubMed ID: 19707830
[TBL] [Abstract][Full Text] [Related]
19. Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
Runner RP; Gottschalk MB; Staley CA; Pour AE; Roberson JR
J Arthroplasty; 2019 Apr; 34(4):729-734. PubMed ID: 30685257
[TBL] [Abstract][Full Text] [Related]
20. CRISTAL: protocol for a cluster randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study.
Sidhu VS; Graves SE; Buchbinder R; Naylor JM; Pratt NL; de Steiger RS; Chong BH; Ackerman IN; Adie S; Harris A; Hansen A; Cripps M; Lorimer M; Webb S; Clavisi O; Griffith EC; Anandan D; O'Donohue G; Kelly TL; Harris IA
BMJ Open; 2019 Nov; 9(11):e031657. PubMed ID: 31699735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
